Steve Horvath

Steve Horvath spent his academic career as Professor of Human Genetics and Biostatistics at UCLA before moving to Altos Labs, the well-funded longevity biotechnology company, as a principal investigator at its Cambridge Institute of Science [1].

Horvath's foundational contribution to the field of epigenetic aging clocks is his 2013 paper, "DNA methylation age of human tissues and cell types," published in Genome Biology [2]. The paper built the first pan-tissue human epigenetic clock, meaning a single mathematical model that could estimate biological age from DNA methylation patterns across many different tissue and cell types rather than requiring a separate model per tissue [2]. Horvath trained the clock using roughly 8,000 samples spanning 82 separate datasets and 51 different tissue and cell types, and reported that the clock's age estimate was near zero for embryonic stem cells and induced pluripotent stem cells (iPSCs), consistent with the idea that reprogramming resets a cell's epigenetic age, a finding later cited extensively by reprogramming researchers, including Vittorio Sebastiano, also profiled in this reference [2].

Horvath had earlier developed the first saliva-based epigenetic clock in 2011, demonstrating that DNA methylation age estimation was feasible from an easily collected, non-invasive sample type, an important practical step toward the consumer and clinical biological-age tests now on the market [1]. In 2021 he led development of the first pan-mammalian epigenetic clock, a model trained across many mammalian species simultaneously rather than only in humans, which allows comparative aging research across species with very different maximum lifespans, from mice to whales [1].

Horvath also co-developed GrimAge, and later GrimAge version 2, with collaborators including Ake T. Lu [4]. Unlike Horvath's original pan-tissue clock, which was trained to predict chronological age itself, GrimAge was trained to predict time-to-death and time-to-disease-onset directly, incorporating DNA methylation-based surrogate estimates of biomarkers including C-reactive protein (a marker of inflammation) and hemoglobin A1c (a marker of blood sugar control) [4]. This made GrimAge one of the strongest mortality-predictive epigenetic clocks in the field when it was published, and GrimAge or GrimAge2 scores are now widely used as secondary outcome measures in longevity intervention trials, including some of the same fasting-mimicking diet studies associated with Valter Longo's group [4].

At Altos Labs, Horvath's research has moved toward using epigenetic clocks as a readout for evaluating cellular reprogramming interventions, directly connecting his biomarker development work to the company's core reprogramming-based rejuvenation research program, alongside colleagues such as Morgan Levine [1]. As with other Altos-affiliated researchers profiled in this reference, work conducted inside the company is not published with the same frequency or openness as Horvath's earlier UCLA-era output, making his most recent research harder for outside scientists to independently evaluate in real time.

The plain takeaway: Horvath's original epigenetic clocks are among the most cited, most independently replicated tools in the entire aging-biomarker field, used by academic labs with no commercial tie to Horvath or Altos Labs; his current work inside a private, well-capitalized company is a different kind of research environment than the open academic publishing that built his reputation, and outside observers should weight his UCLA-era, fully published work more heavily than any unpublished internal Altos findings when evaluating specific claims.